Jose-Maria Abellan-Perpiñan, Esther Redondo Margüello, Ángel Gil de Miguel, Iván Sanz Muñoz, Ariadna Diaz-Aguiló, Paloma Palomo, Manel Farré, Daniel Callejo, Marco Pinel, Juan Luis López-Belmonte
{"title":"Cost-effectiveness analysis of influenza vaccination with high-dose vaccine versus standard-dose quadrivalent vaccine in older adults in Spain.","authors":"Jose-Maria Abellan-Perpiñan, Esther Redondo Margüello, Ángel Gil de Miguel, Iván Sanz Muñoz, Ariadna Diaz-Aguiló, Paloma Palomo, Manel Farré, Daniel Callejo, Marco Pinel, Juan Luis López-Belmonte","doi":"10.1007/s10198-026-01894-8","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction and objectives: </strong>Influenza is a widespread acute respiratory illness which represents a significant public health challenge from both the National Health Service (NHS) and societal perspective, especially in the older adults. The aim of this study was to assess the cost-effectiveness of influenza vaccination with a high-dose quadrivalent vaccine (HD-QIV) versus a standard dose quadrivalent vaccine (SD-QIV) in the older adults in Spain.</p><p><strong>Methods: </strong>We assessed the public health and economic benefits of various alternatives using a decision-tree model. This model considered factors such as influenza cases, visits to general practitioners (GP), emergency department (ED) visits, hospitalizations due to cardiorespiratory events, and influenza-related mortality. To address uncertainties deriving from both epidemiological and economic sources, we conducted deterministic and probabilistic sensitivity analyses.</p><p><strong>Results: </strong>From a societal perspective, HD-QIV compared to SD-QIV prevented during an influenza season 54,039 influenza cases, 7,733 GP consultations, 1,585 ED visits, 30,772 episodes of hospitalization due to cardiorespiratory events over a single influenza season and 1,203 deaths when vaccinating adults ≥ 65 years old in Spain, resulting in 14,316 LYs and 12,545 QALYs gained over a lifetime horizon. The reduction in health outcomes outweighed the increase in vaccination costs, translating to a reduction in total costs with HD-QIV compared to SD-QIV. Therefore, vaccinating older adults in Spain with HD-QIV instead of SD-QIV was a dominant strategy when evaluating hospitalizations due to cardiorespiratory events. HD-QIV remained dominant from an NHS perspective. Sensitivity analyses confirmed the robustness of the model.</p><p><strong>Conclusions: </strong>This analysis showed that vaccinating older adults in Spain with HD-QIV instead of SD-QIV would reduce cases of influenza, GP and ED visits, hospitalizations, deaths, and associated costs, and thus it should be the strategy of choice in a situation of budgetary constraints from either a societal or an NHS perspective.</p>","PeriodicalId":51416,"journal":{"name":"European Journal of Health Economics","volume":" ","pages":"1497-1508"},"PeriodicalIF":3.1000,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13619801/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"European Journal of Health Economics","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s10198-026-01894-8","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2026/3/4 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"ECONOMICS","Score":null,"Total":0}
引用次数: 0
Abstract
Introduction and objectives: Influenza is a widespread acute respiratory illness which represents a significant public health challenge from both the National Health Service (NHS) and societal perspective, especially in the older adults. The aim of this study was to assess the cost-effectiveness of influenza vaccination with a high-dose quadrivalent vaccine (HD-QIV) versus a standard dose quadrivalent vaccine (SD-QIV) in the older adults in Spain.
Methods: We assessed the public health and economic benefits of various alternatives using a decision-tree model. This model considered factors such as influenza cases, visits to general practitioners (GP), emergency department (ED) visits, hospitalizations due to cardiorespiratory events, and influenza-related mortality. To address uncertainties deriving from both epidemiological and economic sources, we conducted deterministic and probabilistic sensitivity analyses.
Results: From a societal perspective, HD-QIV compared to SD-QIV prevented during an influenza season 54,039 influenza cases, 7,733 GP consultations, 1,585 ED visits, 30,772 episodes of hospitalization due to cardiorespiratory events over a single influenza season and 1,203 deaths when vaccinating adults ≥ 65 years old in Spain, resulting in 14,316 LYs and 12,545 QALYs gained over a lifetime horizon. The reduction in health outcomes outweighed the increase in vaccination costs, translating to a reduction in total costs with HD-QIV compared to SD-QIV. Therefore, vaccinating older adults in Spain with HD-QIV instead of SD-QIV was a dominant strategy when evaluating hospitalizations due to cardiorespiratory events. HD-QIV remained dominant from an NHS perspective. Sensitivity analyses confirmed the robustness of the model.
Conclusions: This analysis showed that vaccinating older adults in Spain with HD-QIV instead of SD-QIV would reduce cases of influenza, GP and ED visits, hospitalizations, deaths, and associated costs, and thus it should be the strategy of choice in a situation of budgetary constraints from either a societal or an NHS perspective.
期刊介绍:
The European Journal of Health Economics is a journal of Health Economics and associated disciplines. The growing demand for health economics and the introduction of new guidelines in various European countries were the motivation to generate a highly scientific and at the same time practice oriented journal considering the requirements of various health care systems in Europe. The international scientific board of opinion leaders guarantees high-quality, peer-reviewed publications as well as articles for pragmatic approaches in the field of health economics. We intend to cover all aspects of health economics:
• Basics of health economic approaches and methods
• Pharmacoeconomics
• Health Care Systems
• Pricing and Reimbursement Systems
• Quality-of-Life-Studies The editors reserve the right to reject manuscripts that do not comply with the above-mentioned requirements. The author will be held responsible for false statements or for failure to fulfill the above-mentioned requirements.
Officially cited as: Eur J Health Econ